Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties

作者：Miller Eric J; Mays Suzanne G; Baillie Mark T; Howard Randy B; Culver Deborah G; Saindane Manohar; Pruett Sarah T; Holt Jason J; Menaldino David S; Evers Taylor J; Reddy G Prabhakar; Arrendale Richard F; Natchus Michael G; Petros John A; Liotta Dennis C^*

来源：ACS Medicinal Chemistry Letters, 2016, 7(5): 537-542.

DOI：10.1021/acsmedchemlett.6b00113

• Sphingolipids
• Enigmol
• fluorination
• prostate cancer

The orally bioavailable 1-deoxy-sphingosine analog, Enigmol, has demonstrated anticancer activity in numerous in vivo settings. However, as no Enigmol analog with enhanced potency in vitro has been identified, a new strategy to improve efficacy in vivo by increasing tumor uptake was adopted. Herein, synthesis and biological evaluation of two novel fluorinated Enigmol analogs, CF3-Enigmol and CF2-Enigmol, are reported. Each analog was equipotent to Enigmol in vitro, but achieved higher plasma and tissue levels than Enigmol in vivo. Although plasma and tissue exposures were anticipated to trend with fluorine content, CF2-Enigmol absorbed into tissue at strikingly higher concentrations than CF3-Enigmol. Using mouse xenograft models of prostate cancer, we also show that CF3-Enigmol underperformed Enigmol-mediated inhibition of tumor growth and elicited systemic toxicity. By contrast, CF2-Enigmol was not systemically toxic and demonstrated significantly enhanced antitumor activity as compared to Enigmol.

• 出版日期2016-5